When is it OK to violate your cost basis to buy more shares of a company?

When is it OK to violate your cost basis to buy more shares of a company?


Nvidia CEO Jensen Huang,speaks at the Supermicro keynote presentation during the Computex conference in Taipei on June 1, 2023.

Walid Berrazeg | Sopa Images | Lightrocket | Getty Images

Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries.

This week’s question: The cardinal rule of discipline is to not violate cost basis and show patience to buy more high-quality stocks on pullback. How do you evaluate a flying stock which might not come back to levels of cost basis to add more? Recent examples include Nvidia (NVDA), Eli Lilly (LLY) and Tesla (TSLA). — Thanks, Ravi



Source

Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
Health

Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight.  It could also expand a […]

Read More
‘The next protein’: Fiber is shaping up to be the latest grocery obsession
Health

‘The next protein’: Fiber is shaping up to be the latest grocery obsession

Workers are suspended on a Pepsi sign on a building outside of Allegiant Stadium ahead of LVIII in Las Vegas, Nevada, U.S., February 9, 2024. Brian Snyder | Reuters One of this year’s top food trends is facing some tough competition. Protein captivated consumers and food companies in 2025, but fiber is increasingly stealing the […]

Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More